151 related articles for article (PubMed ID: 7814880)
41. CD4+ T cells mature in the absence of MHC class I and class II expression in Ly-6A.2 transgenic mice.
Henderson SC; Berezovskaya A; English A; Palliser D; Rock KL; Bamezai A
J Immunol; 1998 Jul; 161(1):175-82. PubMed ID: 9647222
[TBL] [Abstract][Full Text] [Related]
42. Dual role of dendritic cells in the induction and down-regulation of antigen-specific cutaneous inflammation.
Krasteva M; Kehren J; Horand F; Akiba H; Choquet G; Ducluzeau MT; Tédone R; Garrigue JL; Kaiserlian D; Nicolas JF
J Immunol; 1998 Feb; 160(3):1181-90. PubMed ID: 9570532
[TBL] [Abstract][Full Text] [Related]
43. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
[TBL] [Abstract][Full Text] [Related]
44. MHC class II-transfected tumor cells directly present antigen to tumor-specific CD4+ T lymphocytes.
Armstrong TD; Clements VK; Ostrand-Rosenberg S
J Immunol; 1998 Jan; 160(2):661-6. PubMed ID: 9551900
[TBL] [Abstract][Full Text] [Related]
45. In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression.
Ishimoto T; Yamamoto K; Fukui Y; Fukuda Y; Dohi K; Sasazuki T
J Immunol; 1997 Oct; 159(8):3717-22. PubMed ID: 9378957
[TBL] [Abstract][Full Text] [Related]
46. Bone marrow-derived macrophage expression of endogenous and transfected class II MHC genes during differentiation in vitro.
Pullen JK; Schook LB
J Immunol; 1986 Aug; 137(4):1359-65. PubMed ID: 3090147
[TBL] [Abstract][Full Text] [Related]
47. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
48. Influence of major histocompatibility complex class I, class II and TLA genes on tumor rejection.
Ostrand-Rosenberg S; Garcia EP; Roby CA; Clements VK
Semin Cancer Biol; 1991 Oct; 2(5):311-9. PubMed ID: 1773047
[TBL] [Abstract][Full Text] [Related]
49. Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genes.
Ostrand-Rosenberg S; Roby C; Clements VK; Cole GA
Int J Cancer Suppl; 1991; 6():61-8. PubMed ID: 1906055
[TBL] [Abstract][Full Text] [Related]
50. New strategies of mammary cancer vaccination.
Accolla RS; Frangione V; De Lerma Barbaro A; Mortara L
Breast J; 2010; 16 Suppl 1():S42-4. PubMed ID: 21050309
[TBL] [Abstract][Full Text] [Related]
51. Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells.
Ostrand-Rosenberg S; Baskar S; Patterson N; Clements VK
Tissue Antigens; 1996 May; 47(5):414-21. PubMed ID: 8795142
[TBL] [Abstract][Full Text] [Related]
52. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.
McBride WH; Thacker JD; Comora S; Economou JS; Kelley D; Hogge D; Dubinett SM; Dougherty GJ
Cancer Res; 1992 Jul; 52(14):3931-7. PubMed ID: 1617669
[TBL] [Abstract][Full Text] [Related]
53. Tissue-specific expression of allogeneic class II MHC molecules induces neither tissue rejection nor clonal inactivation of alloreactive T cells.
Miller J; Daitch L; Rath S; Selsing E
J Immunol; 1990 Jan; 144(1):334-41. PubMed ID: 2136884
[TBL] [Abstract][Full Text] [Related]
54. Association in the expression of Kirsten-ras oncogene and the major histocompatibility complex class I antigens in fibrosarcoma tumor cell variants exhibiting different metastatic capabilities.
Alon Y; Hammerling GJ; Segal S; Bar-Eli M
Cancer Res; 1987 May; 47(10):2553-7. PubMed ID: 3552201
[TBL] [Abstract][Full Text] [Related]
55. T cell responses specific for subregions of allogeneic MHC molecules.
Berkowitz N; Braunstein NS
J Immunol; 1992 Jan; 148(2):309-17. PubMed ID: 1729357
[TBL] [Abstract][Full Text] [Related]
56. Instillation of allogeneic lung antigen-presenting cells deficient in expression of major histocompatibility complex class I or II antigens have differential effects on local cellular and humoral immunity and on pathology in recipient murine lungs.
Heidler KM; Baker K; Woods K; Schnizlein-Bick C; Cummings OW; Sidner R; Foresman B; Wilkes DS
Am J Respir Cell Mol Biol; 2000 Oct; 23(4):499-505. PubMed ID: 11017915
[TBL] [Abstract][Full Text] [Related]
57. Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors.
Flood PM; Schreiber H; Ron Y
J Immunol; 1987 May; 138(10):3573-9. PubMed ID: 3571978
[TBL] [Abstract][Full Text] [Related]
58. Afferent and efferent specificity in the induction and elicitation of parental cross-protective immunity by an immunogenic murine tumor variant: associative recognition of a unique tumor-specific antigen on somatic cell hybrids.
LeGrue SJ; Ananthaswamy HN; Simcik WJ
Cancer Res; 1989 Sep; 49(17):4747-51. PubMed ID: 2474372
[TBL] [Abstract][Full Text] [Related]
59. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one.
Heuer JG; Tucker-McClung C; Gonin R; Hock RA
Hum Gene Ther; 1996 Nov; 7(17):2059-68. PubMed ID: 8934220
[TBL] [Abstract][Full Text] [Related]
60. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice.
Hirahara N; Nio Y; Sasaki S; Minari Y; Takamura M; Iguchi C; Dong M; Yamasawa K; Tamura K
Oncology; 2001; 61(1):79-89. PubMed ID: 11474253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
